MX354535B - TRATAMIENTO DE INFARTO DE MIOCARDIO USANDO ANTAGONISTAS DE TGF-ß. - Google Patents

TRATAMIENTO DE INFARTO DE MIOCARDIO USANDO ANTAGONISTAS DE TGF-ß.

Info

Publication number
MX354535B
MX354535B MX2013002390A MX2013002390A MX354535B MX 354535 B MX354535 B MX 354535B MX 2013002390 A MX2013002390 A MX 2013002390A MX 2013002390 A MX2013002390 A MX 2013002390A MX 354535 B MX354535 B MX 354535B
Authority
MX
Mexico
Prior art keywords
myocardial infarction
tgf
treatment
beta antagonists
patient
Prior art date
Application number
MX2013002390A
Other languages
English (en)
Other versions
MX2013002390A (es
Inventor
Y Akita Geoffrey
Lonning Scott
C Gregory Richard Jr
B Kudej Amelia
Original Assignee
Genzyme Corp Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp Star filed Critical Genzyme Corp Star
Publication of MX2013002390A publication Critical patent/MX2013002390A/es
Publication of MX354535B publication Critical patent/MX354535B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)

Abstract

La presente invención se refiere a un método de tratamiento a un paciente que sufra un infarto de miocardio, particularmente un infarto de miocardio agudo, o para disminuir una consecuencia adversa de un infarto de miocardio en un paciente, que consiste en administrar al paciente un antagonista de TGF-ß durante la etapa aguda del infarto de miocardio.
MX2013002390A 2010-09-01 2011-09-01 TRATAMIENTO DE INFARTO DE MIOCARDIO USANDO ANTAGONISTAS DE TGF-ß. MX354535B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37931510P 2010-09-01 2010-09-01
PCT/US2011/001536 WO2012030394A1 (en) 2010-09-01 2011-09-01 Treatment of myocardial infarction using tgf - beta antagonists

Publications (2)

Publication Number Publication Date
MX2013002390A MX2013002390A (es) 2013-08-27
MX354535B true MX354535B (es) 2018-03-09

Family

ID=44654454

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013002390A MX354535B (es) 2010-09-01 2011-09-01 TRATAMIENTO DE INFARTO DE MIOCARDIO USANDO ANTAGONISTAS DE TGF-ß.

Country Status (19)

Country Link
US (2) US20130330352A1 (es)
EP (1) EP2611831B1 (es)
JP (2) JP6377348B2 (es)
KR (1) KR101939965B1 (es)
CN (1) CN103201292B (es)
BR (1) BR112013004850B1 (es)
CA (1) CA2809568C (es)
CL (1) CL2013000586A1 (es)
ES (1) ES2715177T3 (es)
IL (1) IL225018A (es)
MX (1) MX354535B (es)
MY (1) MY165160A (es)
NZ (2) NZ608813A (es)
PH (1) PH12013500411A1 (es)
PL (1) PL2611831T3 (es)
RU (1) RU2637088C2 (es)
SG (2) SG10201506909PA (es)
TR (1) TR201903101T4 (es)
WO (1) WO2012030394A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011008735A (es) * 2009-02-18 2012-01-12 Cormatrix Cardiovascular Inc Composiciones y metodos para prevenir la arritmia cardiaca.
PL2971048T4 (pl) * 2013-03-11 2019-05-31 Genzyme Corp Zmodyfikowane przeciwciała anty-TGF-beta i fragmenty wiążące antygen
AU2014308751B2 (en) 2013-08-22 2020-03-05 Acceleron Pharma, Inc. TGF-beta receptor type II variants and uses thereof
US11384350B2 (en) 2014-12-15 2022-07-12 The Regents Of The University Of California Cytotoxic molecules responsive to intracellular ligands for selective T cell mediated killing
CA3008162A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
CN116327952A (zh) 2015-08-04 2023-06-27 阿塞勒隆制药公司 用于治疗骨髓增生性病症的方法
DK3368571T5 (da) * 2015-10-30 2024-09-30 Univ California Transformerende, vækstfaktor-beta-responsive polypeptider og fremgangsmåder til anvendelse deraf
WO2017123550A1 (en) * 2016-01-11 2017-07-20 Autotelic Llc Composition, device, and method for detecting olmesartan and improving compliance in treating hypertension
US20170218040A1 (en) * 2016-02-02 2017-08-03 Julio A. Camarero Palao Proteolically resistant cyclotides with angiotensin 1-7 like activity
WO2018027329A1 (en) * 2016-08-11 2018-02-15 Precithera, Inc. TGF-β ANTAGONIST CONJUGATES
BR112019023071A2 (pt) 2017-05-04 2020-06-09 Acceleron Pharma Inc proteínas de fusão do receptor tgf-beta do tipo ii e uso das mesmas
JP2023540382A (ja) * 2020-09-10 2023-09-22 インプリシット・バイオサイエンス・リミテッド 心筋梗塞の処置のための治療方法および治療薬
KR20240082377A (ko) 2021-09-30 2024-06-10 페프티드림 아이엔씨. 펩티드

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
EP1137941B2 (en) 1998-12-10 2013-09-11 Bristol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
US7763580B2 (en) * 1999-01-05 2010-07-27 University Of Utah Research Foundation Methods for treating conditions associated with the accumulation of excess extracellular matrix
CA2561686C (en) * 2004-03-31 2014-12-02 Genentech, Inc. Humanized anti-tgf-beta antibodies
JP2008528626A (ja) 2005-01-31 2008-07-31 マイラン ラボラトリーズ インク． ヒドロキシル化されたネビボロールを含む薬学的組成物
CN101163502A (zh) * 2005-02-08 2008-04-16 根茨美公司 针对TGFβ的抗体
EP2389227A4 (en) * 2009-01-26 2012-08-08 Intermune Inc METHOD FOR THE TREATMENT OF ACUTE MYOCARDINE CARDS AND ASSOCIATED ILLNESSES THEREOF
ITMI20110376A1 (it) 2011-03-10 2012-09-11 Wilic Sarl Aerogeneratore raffreddato a fluido

Also Published As

Publication number Publication date
WO2012030394A1 (en) 2012-03-08
US20170233465A1 (en) 2017-08-17
KR101939965B1 (ko) 2019-01-18
JP2017193543A (ja) 2017-10-26
JP6377348B2 (ja) 2018-08-22
SG187953A1 (en) 2013-03-28
MX2013002390A (es) 2013-08-27
NZ608813A (en) 2014-11-28
TR201903101T4 (tr) 2019-03-21
PL2611831T3 (pl) 2019-05-31
US20130330352A1 (en) 2013-12-12
CL2013000586A1 (es) 2013-08-30
NZ624382A (en) 2015-05-29
BR112013004850A2 (pt) 2016-05-31
BR112013004850B1 (pt) 2020-04-07
AU2011296574A1 (en) 2013-03-21
CN103201292B (zh) 2016-09-14
AU2011296574B2 (en) 2015-12-03
CA2809568C (en) 2019-06-11
EP2611831A1 (en) 2013-07-10
PH12013500411A1 (en) 2022-03-30
RU2637088C2 (ru) 2017-11-29
MY165160A (en) 2018-02-28
IL225018A (en) 2017-11-30
US10633437B2 (en) 2020-04-28
ES2715177T3 (es) 2019-06-03
RU2013114365A (ru) 2014-10-10
JP2013542179A (ja) 2013-11-21
CA2809568A1 (en) 2012-03-08
KR20130111550A (ko) 2013-10-10
EP2611831B1 (en) 2018-12-12
CN103201292A (zh) 2013-07-10
SG10201506909PA (en) 2015-10-29

Similar Documents

Publication Publication Date Title
MX2013002390A (es) Tratamiento de infarto de miocardio usando antagonistas de tgf-beta.
CY1126518T1 (el) Δοσολογικα σχηματα για ενωσεις κατηγοριας εχινοκανδινης
CY1121419T1 (el) Αναστολη της φουκοσυλιωσης των πρωτεϊνων in vivo χρησιμοποιωντας αναλογα φουκοζης
EA201171367A1 (ru) Винилиндазолильные соединения
MA32562B1 (fr) Composes organiques pour la cicatrisation de lesion
EA201390772A1 (ru) Новые соли и полиморфные формы афатиниба
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
PA8852901A1 (es) Inhibidores de proteina cinasa
CY1117678T1 (el) Ενωσεις αναστολεων μεταλλοενζυμου
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
MX355543B (es) Macrociclos peptidomiméticos.
UY34305A (es) Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EA201300583A1 (ru) Вазопротективное и кардиопротективное противодиабетическое лечение
EA201170227A1 (ru) Имидазолкарбоксамиды
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
MX2014001946A (es) Inhibidores del canal de potasio medularmente externo renal.
EA201390428A1 (ru) Композиции и способы лечения легочной гипертензии
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
EA201390799A1 (ru) Триазолопиридины
EA201600495A1 (ru) Пролекарство адреномедуллина на основе полиэтиленгликоля и его применение
CL2012002716A1 (es) Uso de un compuesto inhibidores de dgat1 porque es útil en la prevención, demora del progreso o el tratamiento de una enfermedad o condición seleccionada a partir de quilomicronemia, síndrome de quilomicronemia familiar e hiperlipoproteinemia tipo v; un compuesto derivado de heteroarilo sustituido; composición farmacéutica.
CO6362012A2 (es) Clohidarto de nalmefeno dihidratado

Legal Events

Date Code Title Description
FG Grant or registration